ResearcherInnsbruck Medical UniversityActive in the last 2 years

Irene Johanna Virgolini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7097-6170; OpenAlex author ID A5064747758. Sources: OpenAlex.

Their work

Papers: 2 (first author 0, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 2

Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-617 Radioligand Therapy. Last author DOI 10.1055/a-2221-3220 ↗
Safety and tolerability of 68Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pancreatic ductal adenocarcinoma: the firs… Co-author DOI 10.1007/s00259-020-05045-w ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Giulia Santo · 1 shared paper, 2024 · strength 0.31
- Paper Incidental Finding of a Pancreatic Adenocarcinoma on [68Ga]Ga-PSMA-11 PET/CT in a mCRPC patient under [177Lu]Lu-PSMA-61… DOI 10.1055/a-2221-3220 ↗
Marina Hodolič · 1 shared paper, 2021 · strength 0.16
- Paper Safety and tolerability of 68Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pa… DOI 10.1007/s00259-020-05045-w ↗
Feng Wang · 1 shared paper, 2021 · strength 0.16
- Paper Safety and tolerability of 68Ga-NT-20.3, a radiopharmaceutical for targeting neurotensin receptors, in patients with pa… DOI 10.1007/s00259-020-05045-w ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.